A restriction on the supply of generic medicines to Australia is among genuine risks, regardless of the eventual tariff on pharmaceuticals.

Along with Brigitte Tenni and Belinda Townsend, Collective Member Deborah Gleeson breaks down the consequences of Trump's 'reciprocal tariffs' for access to medicines.

As the Trump administration continues its program of “reciprocal tariffs” and the pharmaceutical industry calls out the Pharmaceutical Benefits Scheme (PBS) and generic drugs, Australian health expert...

The major parties say they won’t use the PBS as a bargaining chip in US tariff negotiations. They also need to resist pressure to slow down access to generic drugs.